Increased prevalence of hypertension among people living with HIV: where to begin?

Aldrey Nascimento Costa[1],[2], Fernando Val[1],[2],[3], Álvaro Elias Macedo[1], Nadia Cubas-Vega[1],[3], Paola López Del Tejo[1],[3], Marly M. Marques[1],[3], Aristóteles Comte de Alencar Filho[2] and Marcus Vinicius Guimarães de Lacerda[1],[4]

[1]. Universidade do Estado do Amazonas, Escola Superior de Ciências da Saúde, Manaus, AM, Brasil.
[2]. Universidade Federal do Amazonas, Manaus, AM, Brasil.
[3]. Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, AM, Brasil.
[4]. Instituto Leônidas & Maria Deane, Fundação Oswaldo Cruz, Manaus, AM, Brasil.

Introduction: Cardiovascular diseases (CDVs) have become increasingly important for progressively older people living with HIV (PLHIV). Identification of gaps requiring improvement in the care cascade for hypertension, a primary risk factor for CVDs, is of utmost importance. This study analyzed the prevalence of hypertensive status and described the care cascade for hypertension screening, diagnosis, treatment, treatment adherence, and management in PLHIV.

Methods: This cross-sectional study included 298 PLHIV (age >40 years) who visited a referral center in the western Brazilian Amazon. Data were collected through a structured questionnaire interview and medical examinations. Thus, information regarding sociodemographic and clinical aspects, blood pressure, weight, height, body mass index, and laboratory profile was obtained. Descriptive and analytical statistics were performed, and results were considered significant if p <0.05.

Results: In total, 132 (44.3%) participants reported that their blood pressure was never measured. The prevalence of hypertension was found to be 35.9% (107/298). Of these 107 participants, only 36 (33.6%) had prior knowledge of their hypertensive status, and 19 of 36 (52.7%) participants had visited a physician or cardiologist to seek treatment. Adherence to the BP-lowering treatment was noted in 11 (10.2%) participants.

Conclusions: An increased prevalence of hypertension was found, and most of the hypertensive participants were unaware of their hypertensive status. In addition, blood pressure control was poor in the study population. This indicated that public health professionals did not sufficiently consider the full spectrum of healthcare and disease management for PLHIV.

Keywords: HIV. Non-communicable diseases. Cardiovascular diseases. Hypertension.

INTRODUCTION

In 2018, the Joint United Nations Programme on HIV/AIDS (UNAIDS) estimated that of approximately 38 million people living with HIV (PLHIV) worldwide, 2.2 million were from Latin America and the Caribbean region1.

The number of PLHIV in Brazil has increased2, despite the efforts and actions taken in recent years to prevent and treat HIV3-5. According to the Brazilian Notification Disease Information System (Sistema de Informação de Agravos de Notificação [SINAN]), the northern region of the country has the highest national rate of newly-diagnosed cases2. This rate is even more significant, considering the difference in population density throughout Brazil. In 2010, the demographic density of the northern region was 4.12, whereas that of the South East region was 86.96.

Increased worldwide coverage of highly active antiretroviral therapy (HAART) has improved patient management and assisted in reducing AIDS mortality; thus, the life expectancy of PLHIV has increased. However, the prevalence of cardiovascular diseases (CVDs) and CVD-related mortality has increased among PLHIV, who are up to two times more likely to present a CVD episode compared with HIV-negative individuals6-9. The pathogenesis of CVD, including hypertension, in PLHIV is a complex interaction between traditional risk factors (dyslipidemia, diabetes, smoking, and sedentary lifestyle), HIV infection (viral activity, decreased...
The hypertension care cascade, and identified possible points of concern and should be addressed urgently. Currently, no treatment strategies that are proven to effectively prevent CVDs in PLHIV are available. Therefore, because CVDs are becoming increasingly important from a public health perspective for progressively older PLHIV, it is of utmost importance to identify stages in the care cascade that require improvement. Therefore, this study analyzed the prevalence of hypertensive status among PLHIV who attended routine follow-up consultations at a referral outpatient care clinic for infectious diseases in the Western Brazilian Amazon, described the hypertension care cascade, and identified possible points of intervention to better address the condition in PLHIV.

METHODS

Study design and ethical considerations

We conducted a cross-sectional study at an HIV/AIDS outpatient clinic in Manaus, Amazonas state, Western Brazilian Amazon. The HIV/AIDS outpatient clinic at the Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, is a tertiary care referral center for infectious diseases. This study was approved by the local Ethical Review Board (approval number: CAAE 76111617.6.0000.0005) and was conducted in compliance with the principles of good clinical practice.

Study participants and data collection

The study was conducted between June 2018 and September 2018. The study population comprised a convenience sample of PLHIV, men and women (age >40 years), who were on antiretroviral treatment, and visited the outpatient clinic for follow-ups. Individuals were invited to participate in the study as they waited for the routine consultation with the infectious disease physician. Individuals who agreed to the study procedures and signed the informed consent form were included in the study. All the participants had their BP measured, self-reported ethnic origin, and received a structured questionnaire interview on sociodemographic data, family income, lifestyle habits, medical history, and medication use. Anthropometric characteristics (height and weight) were verified by the medical team. Height without shoes was measured in centimeters using a stadiometer, and weight, with light clothing and without shoes, was measured in kilograms on a mechanical weighing scale. The body mass index (BMI) was calculated using the measured weight and height. The laboratory profile (total and partial cholesterol, triglycerides, glycemia, creatinine, CD4+ lymphocytes, CD8+ lymphocytes, and viral load) and HIV treatment history were obtained from the hospital’s electronic medical chart.

Study definitions

In our study, hypertension was defined, according to the Brazilian Society of Cardiology, as systolic BP (SBP) ≥140 mmHg or diastolic BP (DBP) ≥90 mmHg. Normal BP was defined as SBP ≤139 mmHg or DBP ≤89 mmHg. A calibrated digital sphygmomanometer was used to measure each participant’s BP. The BP was measured twice, with a 15-minute interval between the two measurements. Participants were asked to quietly sit in an isolated room for 10 minutes before the measurements. To avoid transient elevation in BP secondary to the white-coat syndrome, participants were instructed to be accompanied by a person of their choice during the measurements. BP was independently measured by two researchers. Participants with a history of hypertension were classified as hypertensive, although their BP was within the normal range during the measurement. All the participants, including those classified as normotensive, were asked whether they used BP-lowering medication to avoid classifying them as normotensive.

Further, a structured questionnaire was applied to verify, graphically construct, and analyze the levels of the care cascade received by the participants. The definitions of these levels are described in Table 1.

Statistical analysis

Descriptive statistics were used for demographic and clinical data. Independent t-tests or Wilcoxon-Mann-Whitney and chi-square (χ²) tests were performed to compare groups stratified by two outcomes: normotensive or hypertensive. Continuous variables with normal distribution are described as means and standard deviation and those without normal distribution as medians and interquartile range (IQR). The normality was verified using the Shapiro-Wilk test. The level of confidence was set at 95%. Statistical significance was defined as p <0.05. All statistical analyses were performed using Stata v13 (Stata Corp, College Station, Texas, USA).

RESULTS

This study included 298 PLHIV (men: 215 [72.2%]). The median age of the study population was 52 (IQR: 45-57) years. Further demographic characteristics are presented in Table 2.

The BMI was higher in the hypertensive group than in the normotensive group (p = 0.008). Among 298 participants, 66 (22.1%) were ex-smokers. In total, 52 (78.8%) of 66 ex-smokers were classified into the normotensive group and 14 (21.2%) into hypertensive group (p = 0.005). The plasma level of low-density lipoprotein (LDL) cholesterol was significantly higher in the hypertensive group than in the normotensive group (118 mg/dL...
### TABLE 1: Definitions of the levels of the hypertension care cascade.

| Level     | Definition                                                                 |
|-----------|---------------------------------------------------------------------------|
| Awareness | The patient had been previously informed of their hypertension status by a health professional |
| Care      | The patient had visited an outpatient clinic at least twice in the previous year and was seen by a physician or cardiologist for hypertension treatment |
| Treatment | The patient had already been prescribed blood pressure-lowering drugs |
| Adherence | The patient referred to taking blood pressure-lowering drugs as prescribed by the physician |

Definitions adapted from Prenissi et al. 2019\(^2\) and Wozniak et al. 2016\(^2\).

### TABLE 2: Demographic characteristics of the study population.

| Variables                     | Normotensive (n = 191) | Hypertensive (n = 107) | p-value | All (N = 298) |
|-------------------------------|------------------------|------------------------|---------|---------------|
| **Sex**                       |                        |                        |         |               |
| Male n (%)                    | 137 (71.7)             | 78 (72.9)              | 0.829   | 215 (72.2)    |
| Female n (%)                  | 54 (28.2)              | 29 (27.1)              |         | 83 (27.8)     |
| **Sexual orientation**        |                        |                        |         |               |
| Heterosexual n (%) l          | 120 (62.8)             | 62 (57.9)              |         | 182 (61.1)    |
| Homosexual n (%)              | 45 (23.5)              | 31 (28.9)              | 0.563   | 76 (25.5)     |
| Bisexual n (%)                | 4 (2.2)                | 4 (3.8)                |         | 8 (2.68)      |
| **Age (years) median (IQR)**  | 50 (43–56)             | 53 (48–60)             | 0.001   | 52 (45–57)    |
| **Ethnic Group**              |                        |                        |         |               |
| White n (%)                   | 26 (13.6)              | 11 (10.2)              |         | 37 (12.4)     |
| Black n (%)                   | 19 (9.6)               | 3 (2.8)                | 0.043   | 22 (7.4)      |
| Latino or Hispanic n (%)      | 146 (74.4)             | 93 (86.9)              |         | 239 (80.2)    |
| **Income (R$)**+median (IQR)  | 1000 (950–2000)        | 1200 (900–2100)        | 0.619   | 1092 (900–2000) |
| **Life habits**               |                        |                        |         |               |
| Smoking ¹ n (%)               | 52 (27.2)              | 14 (13)                | 0.005   | 66 (22.1)     |
| Alcohol abuse n (%)           | 77 (40.3)              | 49 (45.8)              | 0.398   | 126 (42.3)    |
| **Family history of hypertension**+ n (%) | 121 (63.3) | 69 (64.4) | 0.513 | 190 (63.7) |
| **BMI median (IQR)**          | 26 (22.7–28.7)         | 27 (24–30)             | 0.008   | 26 (23–29)    |
| **Triglycerides (mg/dL) median (IQR)** | 156 (117–213) | 160 (117–243) | 0.494 | 158 (117–222) |
| **LDL cholesterol (mg/dL) median (IQR)** | 103 (83–128) | 118 (89–142) | 0.019 | 107 (85–135) |
| **Time to HIV diagnosis (years) median (IQR)** | 8 (4–12.5) | 8 (5–13) | 0.701 | 8 (4–13) |
| **Duration of HIV treatment (years) median (IQR)** | 5.5 (3–9) | 7 (4–9) | 0.234 | 6 (0–9) |
| **Nadir CD4+ median (IQR)**   | 235 (109.5–389)        | 272 (119–448)          | 0.341   | 251 (111–420) |
| **CD4+ cell/µL median (IQR)** | 555 (395–787)          | 610 (426–916)          | 0.138   | 571 (410–800) |
| **Viral load median (IQR)**   | 0 (0–0)                | 0 (0–0)                | 0.969   | 0 (0–0)       |

Abbreviations: BMI: body mass index; CD: cluster of differentiation; cm: centimeters; dL: deciliter; HIV: human immunodeficiency virus; LDL: low-density lipoprotein; mg: milligrams; R$: Reais, Brazilian currency; y: years. *32 participants did not declare sexual orientation; **32 participants did not declare income; +3 participants did not declare smoking habits; **66 participants did not know their previous family history of hypertension.
versus 103 mg/dL, \( p = 0.019 \). A total of 260 (87.2%) participants had an undetectable viral load. The median CD4+ count was 571 cells/µL (range: 410-800 cells/µL).

Duration and adherence to HAART varied among study participants. The median treatment time was 6 years (range: 0-27 years), and 256 of 298 (85.9%) participants had a treatment adherence greater than 90%.

**Hypertension care cascade**

A total of 132 (44.3%) participants reported that they had never measured their BP. In total, 191 (64.1%) participants were normotensive (SBP ≤ 139 mmHg or DBP ≤ 89 mmHg) and 107 (35.9%) participants presented signs of systemic hypertension. Among 107 (35.9%) participants diagnosed with hypertension, only 36 (33.6%) had prior knowledge of their hypertensive status and 11 (10.2%) reported adherence to their prescribed BP-lowering treatment. Slightly more than half of these participants (19/36 [52.7%]) had visited a cardiologist or physician to seek treatment, and 17 (89.4%) of these 19 participants had already been prescribed medication. A total of 11 (64.7%) participants who had been prescribed BP-lowering medication presented treatment adherence (Figure 1A and Figure 1B).

**DISCUSSION**

This study revealed that a high proportion of PLHIV who were more than 40 years old had elevated BP. It is estimated that hypertension affects 36 million (32.5%) individuals in Brazil.

The prevalence of hypertensive status among PLHIV in this study was higher than that in the study by Cunha et al.\(^{16}\). Cunha et al. reported that the prevalence of hypertension among HIV outpatients was 17.3%.

Population characteristics and modifiable CVD risk factors may be associated with the hypertensive status among PLHIV. An African study reported that male sex is a significant factor associated with hypertension\(^{17}\). However, male sex was not found to be associated with hypertension in our study. In contrast, the age of the study population was significantly associated with the hypertensive status in the African study as well as in our study. In our study, the median BMI was high, indicating that participants had excess body weight. Being overweight is a modifiable risk factor that was found to be associated with hypertension in the current study, which corroborates with the findings of a study conducted in Poland and another in Nigeria\(^{17,18}\). Smoking, another modifiable CVD risk factor, was found to be significantly associated with the hypertensive status in our study population. However, smoking habits were not reported to be associated with hypertension in PLHIV in Norway\(^{19}\). In Brazil, 9.3% of individuals aged more than 18 years have smoking habits; however, the prevalence is lower (6.4%) in Manaus\(^{20}\). Other factors, such as social, financial, and cultural characteristics of both countries may explain this discrepancy.

Elevated LDL cholesterol level is an established risk factor for atherosclerotic CVD. Strategies to lower LDL cholesterol level include the use of statins and exercise. Both the strategies have been reported to positively enhance lipid and immune status.
and and decrease the level of CVD markers in such a population\textsuperscript{21}. More than half of the study participants had a high LDL cholesterol level, with hypertensive individuals presenting higher levels. Elevated LDL cholesterol levels have been widely associated with increased CVD risk in PLHIV, although not all populations have a high prevalence of hypertension or an association with HIV\textsuperscript{22,23}.

A steep decline was observed in several levels of the care cascade for controlling hypertension in the study population. This reflects a failure of primary health care, although several difficulties could be hampering timely hypertension diagnosis and management in this population. The failure points include the requirement for timely change in well-established risk factors in the primary care approach and the lack of early detection of hypertension. This could be explained by a greater emphasis on HIV care per se and the risk of these patients to develop opportunistic infections followed by a lack of attention to other more common non-communicable diseases (NCD). Nonetheless, a comprehensive and integrative approach for the care of general and specific populations is urgently required\textsuperscript{24}.

Several studies have described possible unified models of NCD and HIV care and treatment in low-income countries\textsuperscript{25}. Implementation feasibility of the proposed models should consider the individual characteristics of health care services. The possible approaches vary from integration of NCD services into HIV care centers to integration of HIV care into primary health care with NCD services and simultaneous integration of both services\textsuperscript{26}. Several measures are to be adopted for successful implementation of each proposed model. However, regardless of the selected model, concerns with respect to human and structural resources, supply chains, and patient education are required to be addressed, with a special focus on early screening, diagnosis, and concomitant effective care.

This study has some limitations. For instance, the inclusion of PLHIV who visited the outpatient clinic may have resulted in the inadequate estimation of the number of hypertensive and normotensive individuals in the general population, leading to the misperception that these results truly reflect the local community. Nonetheless, these results reflect the actual practice patterns and enable a more precise conclusion regarding real-life scenarios in countries with similar economic development and public health care challenges as Brazil.

In conclusion, controlling hypertension is important to minimize CVDs and CVD-related mortality among PLHIV. An increased prevalence of hypertensive status was found in PLHIV, with most of them unaware of it. In addition, several gaps in the hypertension care cascade demonstrated a poor approach to the problem, which should be addressed through a multidisciplinary approach at different levels of public health care. Therefore, an improvement in screening, diagnosis, treatment, and control is urgently required. The provision of highly comprehensive services for the care and treatment of NCDs and HIV is key.

ACKNOWLEDGMENTS

We want to thank all the individuals who generously agreed to participate in this study and the medical staff at the outpatient clinic for helping us with data collection.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

FINANCIAL SUPPORT

The Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM) - 005/2019.

AUTHORS’ CONTRIBUTION

MVL, ANC, and ACAF: Study concept and design; ANC and AEM: Data acquisition; FV and NCV: Data analysis; ANC, FV, NCV, and PLDT: Drafting of the manuscript; MVL, ANC, FV, AEM, NCV, PLDT, MM, and ACAF: Critical revision of the manuscript and approval of the final manuscript.

REFERENCES

1. The Joint United Nations Programme on HIV and AIDS (UNAIDS). UNAIDS Data 2019. Geneva, Switzerland; 2019. 471 p.
2. Ministério da Saúde (MS). Secretaria de Vigilância em Saúde. Sistema Nacional de Vigilância em Saúde - Boletim Epidemiológico HIV/ Aids 2019. Brasília: 2019.
3. Ministério Da Saúde (MS). Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Portaria no. 22, de 25 de maio de 2017. Diário Da União. 2017; 1. 73 p.
4. Ministério Da Saúde (MS). Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Portaria no. 21, de 25 de maio de 2017. Diário Da União. 2017; 1. 73 p.
5. Ministério da Saúde (MS). Secretaria de Vigilância em Saúde. Departamento de Vigilância, Prevenção e Controle das Infecções Sexualmente Transmissíveis, do HIV/Aids e das Hepatites Virais - Protocolo clínico e diretrizes terapêuticas para manejo da infecção pelo HIV em adultos. Brasília: Ministério da Saúde, 2018. 412 p.: il.
6. Instituto Brasileiro de Geografia e Estatística. Censo Demográfico 2010, 2010.
7. Farahani M, Mulinder H, Farahani A, Marlink R. Prevalence and distribution of non-AIDS causes of death among HIV-infected individuals receiving antiretroviral therapy: a systematic review and meta-analysis. Int J STD AIDS. 2016;0(0):1-15.
8. Quiros-Roldán E, Raffetti E, Focà E, Brienasse N, Ferraresi A, Paraninò G, et al. Incidence of cardiovascular events in HIV-positive patients compared to general population over the last decade: a population-based study from 2000 to 2012. AIDS Care. 2016;28(12):1551-8.
9. Suligoi B, Virdone S, Taborelli M, Frova L, Grande E, Grippo F, et al. Excess mortality related to circulatory system diseases and diabetes mellitus among Italian AIDS patients vs. non-AIDS population: a population-based cohort study using the multiple causes-of-death approach. BMC Infect Dis. 2018;18(428):1-8.
10. Vos A, Barth R, Klipstein-Grobusch K, Tempelman H, Devillé W, Dodd C, et al. Cardiovascular disease burden in rural Africa: does HIV and antiretroviral treatment play a role ? J Am Heart Assoc. 2020;9(901):e013466.
11. Butterfield TR, Landay AL, Anzinger JJ. Dysfunctional immunometabolism in HIV infection: contributing factors and implications for age-related comorbid diseases. Curr HIV/AIDS Rep. 2020;17(2):125-37.
12. Nou E, Lo J, Hadigan C, Grinspoon SK. Pathophysiology and management of cardiovascular disease in HIV-infected patients. Lancet Diabetes Endocrinol. 2016;4(7):598-610.
13. Sabapathy K, Hensen B, Varsaneux O, Floyd S, Fidler S, Hayes R. The cascade of care following community-based detection of HIV in sub-Saharan Africa - A systematic review with 90-90-90 targets in sight. PLoS One. 2018;13(7):e0200737.

14. Wozniak G, Khan T, Gillespie C, Sifuentes L, Hasan O, Ritchey M, et al. Hypertension control cascade: a framework to improve hypertension awareness, treatment, and control. J Clin Hypertens. (Greenwich) 2016;18(3):232-9.

15. Sociedade Brasileira de Cardiologia. 7ª Diretriz Brasileira De Hipertensão Arterial. Vol. 107. 2016.

16. Cunha GH, Lima MAC, Galvão MTG, Fecihne FV, Fontenele MSM, Siqueira LR. Prevalence of arterial hypertension and risk factors among people with acquired immunodeficiency syndrome. Rev Lat Am Enfermagem. 2018;26.

17. Isa SE, Kang’ombe AR, Simji GS, Shehu NY, Oche AO, Idoko JA, et al. Hypertension in treated and untreated patients with HIV: a study from 2011 to 2013 at the Jos University Teaching Hospital, Nigeria. Trans R Soc Trop Med Hyg. 2017;111(4):172-7.

18. Rogalska-Płońska M, Rogalski P, Leszczyszyn-Pynka M, Stemkowska J, Kochbach P, Kowalczyk-Kot A, et al. Hypertension, dyslipidaemia, and cardiovascular risk in HIV-infected adults in Poland. Kardiol Pol. 2017;75(12):1324-31.

19. Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-Naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis. 2003;22(12):731-6.

20. Ministerio da Saúde (MS). Secretaria de Vigilância em Saúde. Departamento de Análise em Saúde e Vigilância de Doenças não Transmissíveis. Vigilênt Brasil 2018: Vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico: estimativas sobre frequência e distribuição sociodemográfica de fatores de risco e proteção para doenças crônicas nas capitais dos 26 estados brasileiros e no Distrito Federal em 2018. Brasília: Ministério da Saúde, 2019. 132.: il.

21. Zanetti HR, Gonçalves A, Teixeira Paranhos Lopes L, Mendes EL, Roever L, Silva-Vergara ML, et al. Effects of exercise training and statin use in people living with human immunodeficiency virus with dyslipidemia. Med Sci Sports Exerc. 2020;52(1):16-24.

22. Rückert SCM, Tayea A, Bitilinyu-Bangoh J, Bermúdez-Aza EH, Salumu L, Quiles IA, et al. High rates of hypertension, diabetes, elevated low-density lipoprotein cholesterol, and cardiovascular disease risk factors in HIV-infected patients in Malawi. AIDS. 2018;32(2):253-60.

23. Gelpi M, Afzal S, Lundgren J, Ronit A, Roen A, Mocroft A, et al. Higher risk of abdominal obesity, elevated low-density lipoprotein cholesterol, and hypertriglycerideremia, but not of hypertension, in people living with human immunodeficiency virus (HIV): Results from the copenhagen comorbidity in HIV infection study. Clin Infect Dis. 2018;67(4):579-86.

24. Haldane V, Legido-Quigley H, Chua FLH, Sigfrid L, Murphy G, Ong SE, et al. Integrating cardiovascular diseases, hypertension, and diabetes with HIV services: a systematic review. AIDS Care. 2018;30(1):103-15.

25. Duffy M, Ojikutu B, Andrian S, Sohng E, Minor T, Hirschhorn LR. Non-communicable diseases and HIV care and treatment: models of integrated service delivery. Trop Med Int Heal. 2017;22(8):926-37.

26. Prenissl J, Manne-Goehler J, Jaacks LM, Prabhakaran D, Awasthi A, Bischops AC, et al. Hypertension screening, awareness, treatment, and control in india: a nationally representative cross-sectional study among individuals aged 15 to 49 years. PLoS Med. 2019;16(5):1-18.

27. Wozniak G, Khan T, Gillespie C, Sifuentes L, Hasan O, Ritchey M, et al. Hypertension control cascade: a framework to improve hypertension awareness, treatment, and control. J Clin Hypertens. 2016;18(3):232-9.